- Home
- MDGL vs SRAD Comparison
MDGL vs SRAD Comparison
Compare MDGL & SRAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | SRAD |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 6.8B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MDGL | SRAD |
|---|---|---|
| Price | $582.45 | $23.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 18 |
| Target Price | ★ $580.77 | $30.33 |
| AVG Volume (30 Days) | 274.8K | ★ 1.4M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.54 |
| EPS | N/A | ★ 0.35 |
| Revenue | $740,640,000.00 | ★ $1,440,977,356.00 |
| Revenue This Year | $435.63 | $18.93 |
| Revenue Next Year | $52.56 | $22.19 |
| P/E Ratio | ★ N/A | $69.58 |
| Revenue Growth | ★ 864.21 | 16.74 |
| 52 Week Low | $265.00 | $16.96 |
| 52 Week High | $615.00 | $32.22 |
Technical Indicators
Market Signals| Indicator | MDGL | SRAD |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 57.67 |
| Support Level | $578.00 | $22.86 |
| Resistance Level | $615.00 | $24.17 |
| Average True Range (ATR) | 19.08 | 0.48 |
| MACD | -1.59 | 0.18 |
| Stochastic Oscillator | 63.20 | 79.21 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.